ArticleFrontiers in pharmacology2026
Resveratrol reduces muscle atrophy and stress pathway activation in a combined disuse-hypoxia-mouse model.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Mechanical disuse and hypoxia synergistically worsen muscle atrophy by activating apoptosis, necroptosis, and ER stress pathways. While resveratrol, a natural polyphenol, has shown protective effects in isolated disuse or hypoxia models, its efficacy under combined conditions remains unclear. Methods: Male C57BL/6J mice (4 months old) were assigned to ground control or hindlimb unloading (HU) groups under normoxia (21% O Results: HU-hypoxia significantly reduced muscle mass and function, with upregulation of stress-related genes. Resveratrol showed dose-dependent protection: 20 mg/kg modestly reduced atrophy, while 40 mg/kg nearly preserved muscle mass and strength to control levels under both normoxic and hypoxic conditions. To our knowledge, this is the first study to demonstrate protective effects of resveratrol in a combined HU and hypoxia model of muscle atrophy, accompanied by modulation of apoptosis, necroptosis and ER stress related gene expression. Conclusion: These results suggest that resveratrol may decrease muscle degradation in fast twitch dominant muscles under combined disuse and hypoxia. However, these results are restricted to gastrocnemius muscle in mice, and further investigations in slow twitch muscles and clinical models are required before clinical relevance can be confirmed. These findings support its potential as a therapeutic agent for muscle loss in clinical and spaceflight settings, warranting further translational research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.